Stresscopins and their Uses
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsSheau Yu Hsu, Aaron J.W. Hsueh
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsSheau Yu Hsu, Aaron J.W. Hsueh
Estimating the term…
The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.
A method of treating a metabolic disease comprising administering to a subject in need thereof, a vector comprising a nucleic acid molecule encoding the polypeptide as set forth in SEQ ID NO:5 or 6 or sequences having at least 90% identity to SEQ ID NO:5 or 6.
Dependencies are inferred from the claim text.